In 2020, Bayer and Hua Medicine announced their commercialization agreement and strategic partnership for dorzagliatin, which was approved in September 2022 as the first GK activator in China for treating diabetes under the brand name of HuaTangNing.
2020年，拜耳和华医药宣布了多扎利汀的商业化协议和战略合作伙伴关系，该药物于2022年9月以华汤宁品牌获批为中国首个治疗糖尿病的GK激活剂。
========================================================
部分内容来自网络，如有版权问题请与我们联系
未经许可，严禁转发。QQ交流群：688169419
========================================================